

Giulia Pasello

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6578549/giulia-pasello-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97
papers

1,683
citations

19
h-index

38
g-index

145
ext. papers

2,384
ext. citations

4.5
avg, IF

4.64
L-index

#	Paper	IF	Citations
97	Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario.. <i>ESMO Open</i> , 2022 , 7, 100406	6	2
96	A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERA-VOLT registry.. <i>Journal of Thoracic Oncology</i> , 2022 ,	8.9	1
95	Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?. <i>British Journal of Cancer</i> , 2022 ,	8.7	4
94	SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs.. <i>Frontiers in Oncology</i> , 2022 , 12, 840783	5.3	0
93	The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 169, 103561	7	3
92	Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study. <i>Clinical Lung Cancer</i> , 2021 , 22, 361-370.e3	4.9	4
91	Relapse Patterns and Tailored Treatment Strategies for Malignant Pleural Mesothelioma Recurrence after Multimodality Therapy. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
90	P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment. <i>Frontiers in Oncology</i> , 2021 , 11, 653497	5.3	5
89	Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial. <i>ESMO Open</i> , 2021 , 6, 100051	6	4
88	Diagnostic Challenges in Epithelioid Pleural Mesothelioma: Case Series with Support from Electron Microscopy. <i>Diagnostics</i> , 2021 , 11,	3.8	2
87	How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center. <i>Frontiers in Oncology</i> , 2021 , 11, 669786	5.3	4
86	Immunotherapy in malignant pleural mesothelioma: a review of literature data. <i>Translational Lung Cancer Research</i> , 2021 , 10, 2988-3000	4.4	3
85	Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in -Mutated Non-small Cell Lung Cancer: A Case Report. <i>Frontiers in Medicine</i> , 2021 , 8, 570921	4.9	0
84	Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: Translating scientific evidence into clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 163, 103378	7	2
83	Real-world data on treatment outcomes in -mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. <i>Future Oncology</i> , 2021 , 17, 2513-2527	3.6	0
82	Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model. <i>Thoracic Cancer</i> , 2021 , 12, 13-20	3.2	4
81	Lobectomy With Artery Reconstruction and Pneumonectomy for Non-Small Cell Lung Cancer: A Propensity Score Weighting Study. <i>Annals of Thoracic Surgery</i> , 2021 , 112, 1805-1813	2.7	2

80	Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. <i>Translational Lung Cancer Research</i> , 2021 , 10, 202-220	4.4	13
79	Immune checkpoint inhibitors in mesothelioma: a turning point. <i>Lancet, The</i> , 2021 , 397, 348-349	4.0	5
78	Non-Small-Cell Lung Cancer: Real-World Cost Consequence Analysis. <i>JCO Oncology Practice</i> , 2021 , 17, e1085-e1093	2.3	1
77	Computed Tomography and Spirometry Can Predict Unresectability in Malignant Pleural Mesothelioma. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
76	First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. <i>Oncologist</i> , 2021 ,	5.7	3
75	Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification. <i>Cytokine</i> , 2021 , 146, 155622	4	0
74	Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 1438-1447	21.7	18
73	1900P RAMES trial: A multicentre, double-blind, randomized, phase II study on gemcitabine plus ramucirumab versus gemcitabine alone as second-line treatment for advanced malignant pleural mesothelioma (MPM). <i>Annals of Oncology</i> , 2020 , 31, S1078	10.3	2
72	1939P Potential role of longitudinal plasma next generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) experiencing hyperprogression (HPD) and early death (ED) during treatment with immune checkpoint inhibitors (ICIs). <i>Annals of Oncology</i> , 2020 , 31, S1096	10.3	2
71	Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2020 , 123, 81-91	8.7	23
70	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology, The</i> , 2020 , 21, 914-922	21.7	328
69	Immunohistochemical neuroendocrine marker expression in primary pulmonary NUT carcinoma: a diagnostic pitfall. <i>Histopathology</i> , 2020 , 77, 508-510	7.3	6
68	Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience. <i>Oncologist</i> , 2020 , 25, e1996-e2005	5.7	11
67	Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
66	PET/CT and the Response to Immunotherapy in Lung Cancer. <i>Current Radiopharmaceuticals</i> , 2020 , 13, 177-184	1.8	9
65	SMO mutations confer poor prognosis in malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , 2020 , 9, 1940-1951	4.4	0
64	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020 , 12,	6.6	3
63	Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. <i>Cancer Treatment Reviews</i> , 2020 , 87, 102031	14.4	37

62	Metabolic rewiring and redox alterations in malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2020 , 122, 52-61	8.7	8
61	A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Diagnostics</i> , 2020 , 10,	3.8	6
60	Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 564915	5.3	4
59	Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. <i>Cancers</i> , 2020 , 12,	6.6	11
58	SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020 , 9, 1810-1821	4.4	4
57	Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare Histological Subtypes (CHANCE trial). <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920914983 ²	5.4	2
56	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. <i>Clinical Lung Cancer</i> , 2020 , 21, 1-14.e3	4.9	10
55	Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives. <i>Frontiers in Oncology</i> , 2019 , 9, 740	5.3	14
54	Does Induction Therapy Increase Anastomotic Complications in Bronchial Sleeve Resections?. <i>World Journal of Surgery</i> , 2019 , 43, 1385-1392	3.3	7
53	LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	20
52	Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 138, 87-103	7	8
51	Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges 2019 , 7, 205		41
50	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 1655-1669	21.7	215
49	From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for -Positive Non-Small Cell Lung Cancer (MOST Study). <i>Oncologist</i> , 2019 , 24, e318-e326	5.7	3
48	Targeted Therapies in Mesothelioma 2019 , 243-259		
47	Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20612-e20612	2.2	
46	Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. <i>Oncologist</i> , 2019 , 24, 1128-1136	5.7	68
45	18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy. <i>Nuclear Medicine Communications</i> , 2019 , 40, 802-807	1.6	43

44	Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy. <i>Journal of Thoracic Oncology</i> , 2019 , 14, e5-e7	8.9	6
43	Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time. <i>Annals of Oncology</i> , 2018 , 29, 1258-1265	10.3	51
42	Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer. <i>Clinical Lung Cancer</i> , 2018 , 19, 191-198	4.9	1
41	The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes. <i>European Journal of Cancer</i> , 2018 , 101, 191-200	7.5	44
40	RELEVANT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. <i>Clinical Lung Cancer</i> , 2018 , 19, e811-e814	4.9	10
39	Monitoring advanced non-small cell lung cancer (NSCLC) through plasma genotyping during systemic treatment: KRAS-mutated (m) cohort results.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e24074-e24074	2.2	70
38	Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2018 , 36, 342-349	2.2	70
37	Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). <i>Cancer Treatment Reviews</i> , 2018 , 71, 76-87	14.4	17
36	Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1750-1761	8.9	14
35	Liquid biopsy as tool to monitor and predict clinical benefit from chemotherapy (CT) and immunotherapy (IT) in advanced non-small cell lung cancer (aNSCLC): A prospective study. <i>Annals of Oncology</i> , 2018 , 29, viii649	10.3	8
34	Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 128, 19-29	7	7
33	Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma. <i>Oncology Research and Treatment</i> , 2017 , 40, 364-369	2.8	3
32	Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab. <i>European Journal of Dermatology</i> , 2017 , 27, 205-208	0.8	12
31	Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. <i>Oncotarget</i> , 2017 , 8, 32626-32638 ¹⁴	3.3	14
30	Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists. <i>Oncotarget</i> , 2017 , 8, 44232-44241	3.3	9
29	Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 97, 220-30	7	35
28	A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with Afatinib. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e63-e64	8.9	11
27	Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization. <i>Oncotarget</i> , 2016 , 7, 25050-63	3.3	6

26	Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment. <i>OncoTargets and Therapy</i> , 2016 , 9, 3671-81	4.4	2
25	Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature. <i>Experimental and Therapeutic Medicine</i> , 2016 , 11, 197-200	2.1	5
24	Results of surgical resection after induction chemoradiation for Pancoast tumours □ <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2015 , 20, 805-11; discussion 811-2	1.8	14
23	Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature. <i>American Journal of Case Reports</i> , 2015 , 16, 782-9	1.3	7
22	MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data. <i>Oncotarget</i> , 2015 , 6, 42053-66	3.3	9
21	Clinicopathological features of patients with malignant mesothelioma in a multicenter, retrospective study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e12651-e12651	2.2	
20	Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey. <i>British Journal of Cancer</i> , 2014 , 111, 220-6	8.7	28
19	COPD-related adenocarcinoma presents low aggressiveness morphological and molecular features compared to smoker tumours. <i>Lung Cancer</i> , 2014 , 86, 311-7	5.9	11
18	Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1008-1017	8.9	8
17	Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2014 , 19, 256-62; discussion 262	1.8	14
16	Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7527-7527	2.2	14
15	Clinicopathologic features of patients with malignant mesothelioma in a multicenter, retrospective study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e18544-e18544	2.2	
14	An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma. <i>Cancer Treatment Reviews</i> , 2013 , 39, 10-7	14.4	18
13	Effects of sulfonylureas on tumor growth: a review of the literature. <i>Oncologist</i> , 2013 , 18, 1118-25	5.7	38
12	Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2013 , 44, 104-10	3	2
11	Malignant pleural mesothelioma (MPM) in elderly patients: A multicenter survey.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7082-7082	2.2	
10	Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience. <i>Lung Cancer</i> , 2011 , 73, 351-5	5.9	10
9	DNA copy number profile discriminates between esophageal adenocarcinoma and squamous cell carcinoma and represents an independent prognostic parameter in esophageal adenocarcinoma. <i>Cancer Letters</i> , 2011 , 310, 84-93	9.9	14

8	Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis. <i>European Journal of Cancer</i> , 2011 , 47, 326-32	7.5	46
7	Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. <i>Annals of Oncology</i> , 2011 , 22, 1528-1534	10.3	42
6	Preoperative concomitant chemo-radiotherapy in superior sulcus tumour: A mono-institutional experience. <i>Lung Cancer</i> , 2010 , 68, 228-33	5.9	5
5	Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. <i>Anticancer Research</i> , 2010 , 30, 5121-8	2.3	35
4	Second and third line treatment in non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 71, 117-26	7	7
3	DNA copy number alterations correlate with survival of esophageal adenocarcinoma patients. <i>Modern Pathology</i> , 2009 , 22, 58-65	9.8	22
2	Molecular targets in malignant pleural mesothelioma treatment. <i>Current Drug Targets</i> , 2009 , 10, 1235-44		22
1	Second and third line treatment in advanced non-small cell lung cancer. <i>Discovery Medicine</i> , 2009 , 8, 204-25		10